Pentax Canada Inc

WVU Cancer Institute Pioneers Esophageal Cancer Prevention with Cryoballoon Device

6 months ago

• WVU Cancer Institute is the first to commercially use the FDA-approved 180° C2 Cryoballoon for Barrett's esophagus treatment, a precancerous condition. • The Cryoballoon offers a targeted, minimally invasive cryotherapy, freezing and eliminating abnormal esophageal cells with enhanced precision and safety. • The technology represents a significant advancement in endoscopic treatments, providing new possibilities for at-risk patients and effective treatment options. • The first patient treated with the device experienced a quick recovery, demonstrating the potential for improved patient outcomes and reduced recovery time.